Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D06PNU
|
||||
| Former ID |
DNC006335
|
||||
| Drug Name |
Tic-D-Phe-Arg-2-Nal-NHCH3
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C39H46N8O4
|
||||
| Canonical SMILES |
CNC(=O)C(CC1=CC2=CC=CC=C2C=C1)NC(=O)C(CCCN=C(N)N)NC(=O)<br />C(CC3=CC=CC=C3)NC(=O)C4CC5=CC=CC=C5CN4
|
||||
| InChI |
1S/C39H46N8O4/c1-42-35(48)33(22-26-17-18-27-12-5-6-13-28(27)20-26)46-36(49)31(16-9-19-43-39(40)41)45-38(51)34(21-25-10-3-2-4-11-25)47-37(50)32-23-29-14-7-8-15-30(29)24-44-32/h2-8,10-15,17-18,20,31-34,44H,9,16,19,21-24H2,1H3,(H,42,48)(H,45,51)(H,46,49)(H,47,50)(H4,40,41,43)/t31-,32-,33-,34+/m0/s1
|
||||
| InChIKey |
MCHDZFRIUNRJGL-GZXHTMMISA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Melanocyte stimulating hormone receptor | Target Info | Inhibitor | [1] | |
| Melanocortin-4 receptor | Target Info | Inhibitor | [1] | ||
| Melanocortin-3 receptor | Target Info | Inhibitor | [1] | ||
| KEGG Pathway | Neuroactive ligand-receptor interaction | ||||
| Melanogenesishsa04080:Neuroactive ligand-receptor interactionhsa04080:Neuroactive ligand-receptor interaction | |||||
| Pathway Interaction Database | Syndecan-3-mediated signaling events | ||||
| Reactome | Peptide ligand-binding receptors | ||||
| G alpha (s) signalling eventsR-HSA-375276:Peptide ligand-binding receptors | |||||
| G alpha (s) signalling events | |||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | ||||
| Peptide GPCRs | |||||
| GPCR ligand binding | |||||
| GPCR downstream signalingWP455:GPCRs, Class A Rhodopsin-like | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | Bioorg Med Chem Lett. 2006 Mar 15;16(6):1721-5. Epub 2005 Dec 20.Synthesis of Tic-D-Phe Psi[CH2-CH2] isostere and its use in the development of melanocortin receptor agonists. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.